London Daily

Focus on the big picture.
Thursday, Oct 30, 2025

UK biotech hails milestone in hunt for jab to combat  peanut allergies

UK biotech hails milestone in hunt for jab to combat peanut allergies

ABRITISH biotech spun out from SmithKline Beecham in the 1990s is on the brink of a breakthrough in the hunt for the “holy grail” of allergy research - a vaccine for peanut allergy sufferers.

AIM-listed Allergy Therapeutics, based in Worthing, is seeking permission with the US Food and Drug Administration regulator to begin human trials of its short-course jab next year following the publication of results from tests run in collaboration with London’s Imperial College.

The treatment uses a plant-based Cucumber Mosaic Virus engineered to display the key allergen which triggers what can be a potentially life-threatening anaphylactic over-reaction in sufferers.

These virus-like particles (VLPs) train the patient’s immune system to produce protective antibodies against the allergen, in the same way traditional vaccinations protect against invading viruses, which dampen down the response.

Allergy Therapeutics


Results from the Imperial study showed a 24-fold reduction in the activation of infection-fighting white blood cells (basophils) and histamine release after blood samples from allergy patients were challenged with the vaccine.

A short-course treatment of shots would pave the way for a major shift in how one of the most common types of food allergies - whose symptoms can range from mild to severe and life-threatening - is managed.

Around 2% of children in the UK are affected by the condition, of whom only around a fifth outgrow it by the time they reach school age.

The prevalence of peanut allergy doubled between 2005 and 2015 and it is the most common cause of severe and fatal food-induced anaphylactic reactions in the US.

Allergy Therapeutics believes successful human trials will open up opportunities to enter the $8 billion worldwide food allergy market.

Early research is also underway to establish its potential application in oncology and immune conditions such as asthma and psoriasis.

The immunotherapy specialist was formed in 1999, spun out of GSK’s predecessor, and last year recorded sales of £78 million for its portfolio of therapies for mostly pollen-related allergies.

Manuel Llobet, CEO of Allergy Therapeutics, said: “We are pleased to have reached this important milestone in the development of our ground-breaking and disruptive vaccine candidate, VLP Peanut.

“Through our collaboration with Imperial College London and the dedication of our clinical and R&D teams at Allergy Therapeutics, we are another step closer to offering a potentially transformative treatment option for one of the most dangerous allergies.

“I am proud of the work we do in helping to transform patients’ lives and look forward to our upcoming Investigational New Drug submission at the end of this year and expected initiation of our Phase I trial in 2022.”

Shares in Allergy Therapeutics were up 5.59% at 28.35p today.

Newsletter

Related Articles

0:00
0:00
Close
UK and Vietnam Sign Landmark Migration Deal to Fast-Track Returns of Irregular Arrivals
UK Drug-Pricing Overhaul Essential for Life-Sciences Ambition, Says GSK Chief
Princesses Beatrice and Eugenie Temporarily Leave the UK Amid Their Parents’ Royal Fallout
UK Weighs Early End to Oil and Gas Windfall Tax as Reeves Seeks Investment Commitments
UK Retail Inflation Slows as Shop Prices Fall for First Time Since Spring
Next Raises Full-Year Profit Guidance After Strong Third-Quarter Performance
Reform UK’s Lee Anderson Admits to 'Gaming' Benefits System While Advocating Crackdown
United States and South Korea Conclude Major Trade Accord Worth $350 Billion
Hurricane Melissa Strikes Cuba After Devastating Jamaica With Record Winds
Vice President Vance to Headline Turning Point USA Campus Event at Ole Miss
U.S. Targets Maritime Narco-Routes While Border Pressure to Mexico Remains Limited
Bill Gates at 70: “I Have a Real Fear of Artificial Intelligence – and Also Regret”
Elon Musk Unveils Grokipedia: An AI-Driven Alternative to Wikipedia
Saudi Arabia Unveils Vision for First-Ever "Sky Stadium" Suspended Over Desert Floor
Amazon Announces 14 000 Corporate Job Cuts as AI Investment Accelerates
UK Shop Prices Fall for First Time Since March, Food Leads the Decline
London Stock Exchange Group ADR (LNSTY) Earns Zacks Rank #1 Upgrade on Rising Earnings Outlook
Soap legend Tony Adams, long-time star of Crossroads, dies at 84
Rachel Reeves Signals Tax Increases Ahead of November Budget Amid £20-50 Billion Fiscal Gap
NatWest Past Gains of 314% Spotlight Opportunity — But Some Key Risks Remain
UK Launches ‘Golden Age’ of Nuclear with £38 Billion Sizewell C Approval
UK Announces £1.08 Billion Budget for Offshore Wind Auction to Boost 2030 Capacity
UK Seeks Steel Alliance with EU and US to Counter China’s Over-Capacity
UK Struggles to Balance China as Both Strategic Threat and Valued Trading Partner
Argentina’s Markets Surge as Milei’s Party Secures Major Win
British Journalist Sami Hamdi Detained by U.S. Authorities After Visa Revocation Amid Israel-Gaza Commentary
King Charles Unveils UK’s First LGBT+ Armed Forces Memorial at National Memorial Arboretum
At ninety-two and re-elected: Paul Biya secures eighth term in Cameroon amid unrest
Racist Incidents Against UK Nurses Surge by 55%
UK Chancellor Rachel Reeves Cites Shared Concerns With Trump Administration as Foundation for Early US-UK Trade Deal
Essentra plc: A Closer Look at a UK ‘Penny Stock’ Opportunity Amid Market Weakness
U.S. and China Near Deal to Avert Rare-Earth Export Controls Ahead of Trump-Xi Summit
Justin time: Justin Herbert Shields Madison Beer with Impressive Reflex at Lakers Game
Russia’s President Putin Declares Burevestnik Nuclear Cruise Missile Ready for Deployment
Giuffre’s Memoir Alleges Maxwell Claimed Sexual Act with Clooney
House Republicans Move to Strip NYC Mayoral Front-Runner Zohran Mamdani of U.S. Citizenship
Record-High Spoiled Ballots Signal Voter Discontent in Ireland’s 2025 Presidential Election
Philippines’ Taal Volcano Erupts Overnight with 2.4 km Ash Plume
Albania’s Virtual AI 'Minister' Diella Set to 'Birth' Eighty-Three Digital Assistants for MPs
Tesla Unveils Vision for Optimus V3 as ‘Biggest Product of All Time’, Including Surgical Capabilities
Francis Ford Coppola Auctions Luxury Watches After Self-Financed Film Flop
Convicted Sex Offender Mistakenly Freed by UK Prison Service Arrested in London
United States and China Begin Constructive Trade Negotiations Ahead of Trump–Xi Summit
U.S. Treasury Sanctions Colombia’s President Gustavo Petro over Drug-Trafficking Allegations
Miss USA Crowns Nebraska’s Audrey Eckert Amid Leadership Overhaul
‘I Am Not Done’: Kamala Harris Signals Possible 2028 White House Run
NBA Faces Integrity Crisis After Mass Arrests in Gambling Scandal
Swift Heist at the Louvre Sees Eight French Crown Jewels Stolen in Under Seven Minutes
U.S. Halts Trade Talks with Canada After Ontario Ad Using Reagan Voice Triggers Diplomatic Fallout
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
×